224 related articles for article (PubMed ID: 32652867)
21. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
22. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
[TBL] [Abstract][Full Text] [Related]
23. Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt/β-catenin and NF-κB signaling pathway.
Wang Y; Bao X; Zhao A; Zhang J; Zhang M; Zhang Q; Ma B
Life Sci; 2018 Aug; 207():532-549. PubMed ID: 29972765
[TBL] [Abstract][Full Text] [Related]
24. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
25. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F
Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879
[TBL] [Abstract][Full Text] [Related]
26. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
[TBL] [Abstract][Full Text] [Related]
27. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer.
Huang Y; Chan S; Chen S; Liu X; Li M; Zheng L; Dong Z; Yang Z; Liu Z; Zhou D; Zhang X; Zhang B
J Transl Med; 2024 Feb; 22(1):133. PubMed ID: 38310229
[TBL] [Abstract][Full Text] [Related]
28. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
29. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.
Cho YH; Ro EJ; Yoon JS; Mizutani T; Kang DW; Park JC; Il Kim T; Clevers H; Choi KY
Nat Commun; 2020 Oct; 11(1):5321. PubMed ID: 33087710
[TBL] [Abstract][Full Text] [Related]
30. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133
Klose J; Eissele J; Volz C; Schmitt S; Ritter A; Ying S; Schmidt T; Heger U; Schneider M; Ulrich A
BMC Cancer; 2016 Nov; 16(1):896. PubMed ID: 27855654
[TBL] [Abstract][Full Text] [Related]
31. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
32. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
Pothuraju R; Rachagani S; Krishn SR; Chaudhary S; Nimmakayala RK; Siddiqui JA; Ganguly K; Lakshmanan I; Cox JL; Mallya K; Kaur S; Batra SK
Mol Cancer; 2020 Feb; 19(1):37. PubMed ID: 32098629
[TBL] [Abstract][Full Text] [Related]
33. MiR-346-5p promotes colorectal cancer cell proliferation in vitro and in vivo by targeting FBXL2 and activating the β-catenin signaling pathway.
Pan S; Wu W; Ren F; Li L; Li Y; Li W; Wang A; Liu D; Dong Y
Life Sci; 2020 Mar; 244():117300. PubMed ID: 31953162
[TBL] [Abstract][Full Text] [Related]
34. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
35. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells.
Wang T; Chen Z; Zhu Y; Pan Q; Liu Y; Qi X; Jin L; Jin J; Ma X; Hua D
J Biol Chem; 2015 Jan; 290(1):448-56. PubMed ID: 25404731
[TBL] [Abstract][Full Text] [Related]
37. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
[TBL] [Abstract][Full Text] [Related]
38. FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer.
Peng X; Luo Z; Kang Q; Deng D; Wang Q; Peng H; Wang S; Wei Z
Cancer Biol Ther; 2015; 16(7):1099-109. PubMed ID: 25955104
[TBL] [Abstract][Full Text] [Related]
39. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
[TBL] [Abstract][Full Text] [Related]
40. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway.
Liu C; Zhao Y; Wang J; Yang Y; Zhang Y; Qu X; Peng S; Yao Z; Zhao S; He B; Mi Q; Zhu Y; Liu X; Zou J; Zhang X; Du Q
Cancer Lett; 2020 Feb; 470():29-42. PubMed ID: 31811910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
